

ABSTRACT OF THE DISCLOSURE

This invention is directed to methods for providing sustained
systemic concentrations of therapeutic or prophylactic agents such as GABA
5 analogs following oral administration to animals. This invention is also
directed to compounds and pharmaceutical compositions that are used in
such methods.

10

FOOTNOTES

7